{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T07:44:28Z","timestamp":1788335068237,"version":"build-2803163510"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T00:00:00Z","timestamp":1670457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T00:00:00Z","timestamp":1670457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004243","name":"Prinses Beatrix Spierfonds","doi-asserted-by":"publisher","award":["W.OR16\u201307"],"award-info":[{"award-number":["W.OR16\u201307"]}],"id":[{"id":"10.13039\/501100004243","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004243","name":"Prinses Beatrix Spierfonds","doi-asserted-by":"publisher","award":["W.F16-03"],"award-info":[{"award-number":["W.F16-03"]}],"id":[{"id":"10.13039\/501100004243","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["152001005"],"award-info":[{"award-number":["152001005"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Sophia Foundation for Medical Research","award":["S17\u201332"],"award-info":[{"award-number":["S17\u201332"]}]},{"DOI":"10.13039\/100016062","name":"Stichting Metakids","doi-asserted-by":"publisher","award":["2016\u2013063"],"award-info":[{"award-number":["2016\u2013063"]}],"id":[{"id":"10.13039\/100016062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Enzyme replacement therapy has drastically changed prospects of patients with Pompe disease, a progressive metabolic myopathy. As classic infantile patients survive due to treatment, they exhibit progressive white matter abnormalities, while brain involvement in late-onset patients is not fully elucidated. To study the underlying microstructure of white matter, we acquired structural (T1, T2, FLAIR) and diffusion tensor imaging (DTI) of the brain in 12 classic infantile patients (age 5\u201320\u00a0years) and 18 late-onset Pompe patients (age 11\u201356\u00a0years). Structural images were scored according to a rating scale for classic infantile patients. Fractional anisotropy (FA) and mean diffusivity (MD) from classic infantile patients were compared to a reference population, using a Wilcoxon signed-rank, one sample test. Effect sizes (Hedges\u2019 G) were used to compare DTI metrics across different tracts. For late-onset patients, results were compared to (reported) tractography data on normal aging. In classic infantile patients, we found a significant lower FA and higher MD (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01) compared to the reference population. Large-association fibers were most severely affected. Classic infantile patients with advanced white matter abnormalities on structural MRI showed the largest deviations from the reference population. FA and MD were similar for younger and older late-onset patients in large WM-association fibers. We conclude that, while no deviations from typical neurodevelopment were found in late-onset patients, classic infantile Pompe patients showed quantifiable, substantially altered white matter microstructure, which corresponded with disease stage on structural MRI. DTI holds promise to monitor therapy response in future therapies targeting the brain.<\/jats:p>","DOI":"10.1007\/s00415-022-11506-z","type":"journal-article","created":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T16:10:58Z","timestamp":1670515858000},"page":"1662-1671","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Diffusion tensor imaging of the brain in Pompe disease"],"prefix":"10.1007","volume":"270","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0948-7313","authenticated-orcid":false,"given":"Jan J. A.","family":"van den Dorpel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolein H. G.","family":"Dremmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine A. M. E.","family":"van der Beek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitris","family":"Rizopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter A.","family":"van Doorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ans T.","family":"van der Ploeg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan L.","family":"Muetzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna M. P.","family":"van den Hout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,8]]},"reference":[{"key":"11506_CR1","volume-title":"The online metabolic & molecular bases of inherited disease (OMMBID)","author":"AJ Reuser","year":"2018","unstructured":"Reuser AJ, Hirschhorn R, Kroos MA (2018) Pompe disease: glycogen storage disease type II, acid alpha-glucosidase (acid maltase) deficiency. In: Valle D, Beaudet AL, Vogelstein B (eds) The online metabolic & molecular bases of inherited disease (OMMBID). McGraw Hill, New York"},{"issue":"2","key":"11506_CR2","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1542\/peds.112.2.332","volume":"112","author":"HM van den Hout","year":"2003","unstructured":"van den Hout HM et al (2003) The natural course of infantile Pompe\u2019s disease: 20 original cases compared with 133 cases from the literature. Pediatrics 112(2):332\u2013340","journal-title":"Pediatrics"},{"issue":"5","key":"11506_CR3","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.jpeds.2005.11.033","volume":"148","author":"PS Kishnani","year":"2006","unstructured":"Kishnani PS et al (2006) A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J Pediatr 148(5):671\u2013676","journal-title":"J Pediatr"},{"key":"11506_CR4","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/1750-1172-7-88","volume":"7","author":"NA van der Beek","year":"2012","unstructured":"van der Beek NA et al (2012) Clinical features and predictors for disease natural progression in adults with Pompe disease: a nationwide prospective observational study. Orphanet J Rare Dis 7:88","journal-title":"Orphanet J Rare Dis"},{"issue":"9227","key":"11506_CR5","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/S0140-6736(00)02533-2","volume":"356","author":"H Van den Hout","year":"2000","unstructured":"Van den Hout H et al (2000) Recombinant human alpha-glucosidase from rabbit milk in Pompe patients. Lancet 356(9227):397\u2013398","journal-title":"Lancet"},{"issue":"5","key":"11506_CR6","doi-asserted-by":"publisher","first-page":"e448","DOI":"10.1542\/peds.113.5.e448","volume":"113","author":"JM Van den Hout","year":"2004","unstructured":"Van den Hout JM et al (2004) Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk. Pediatrics 113(5):e448\u2013e457","journal-title":"Pediatrics"},{"issue":"2","key":"11506_CR7","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1212\/01.wnl.0000251268.41188.04","volume":"68","author":"PS Kishnani","year":"2007","unstructured":"Kishnani PS et al (2007) Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology 68(2):99\u2013109","journal-title":"Neurology"},{"issue":"6","key":"11506_CR8","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1111\/dmcn.13740","volume":"60","author":"BJ Ebbink","year":"2018","unstructured":"Ebbink BJ et al (2018) Classic infantile Pompe patients approaching adulthood: a cohort study on consequences for the brain. Dev Med Child Neurol 60(6):579\u2013586","journal-title":"Dev Med Child Neurol"},{"issue":"6","key":"11506_CR9","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.pediatrneurol.2010.02.006","volume":"42","author":"TA Burrow","year":"2010","unstructured":"Burrow TA et al (2010) Acute progression of neuromuscular findings in infantile Pompe disease. Pediatr Neurol 42(6):455\u2013458","journal-title":"Pediatr Neurol"},{"issue":"2","key":"11506_CR10","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.ymgme.2017.10.005","volume":"123","author":"PT McIntosh","year":"2018","unstructured":"McIntosh PT et al (2018) Neuroimaging findings in infantile Pompe patients treated with enzyme replacement therapy. Mol Genet Metab 123(2):85\u201391","journal-title":"Mol Genet Metab"},{"key":"11506_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.569153","volume":"11","author":"M Paoletti","year":"2020","unstructured":"Paoletti M et al (2020) Multicentric retrospective evaluation of five classic infantile Pompe disease subjects under enzyme replacement therapy with early infratentorial involvement. Front Neurol 11:569153","journal-title":"Front Neurol"},{"issue":"3","key":"11506_CR12","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1111\/ene.13835","volume":"26","author":"O Musumeci","year":"2019","unstructured":"Musumeci O et al (2019) Central nervous system involvement in late-onset Pompe disease: clues from neuroimaging and neuropsychological analysis. Eur J Neurol 26(3):442-e35","journal-title":"Eur J Neurol"},{"issue":"2","key":"11506_CR13","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ymgme.2019.05.007","volume":"127","author":"I Schneider","year":"2019","unstructured":"Schneider I, Hensel O, Zierz S (2019) White matter lesions in treated late onset Pompe disease are not different to matched controls. Mol Genet Metab 127(2):128\u2013131","journal-title":"Mol Genet Metab"},{"issue":"3","key":"11506_CR14","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1002\/jimd.12469","volume":"45","author":"JJA van den Dorpel","year":"2022","unstructured":"van den Dorpel JJA, van der Vlugt WMC, Dremmen MHG, Muetzel R, van den Berg E, Hest R, de Kriek J, Brusse E, van Doorn PA, van der Ploeg AT, van den Hout JMP, van der Beek NAME (2022) Is the brain involved in patients with late-onset Pompe disease? J Inherited Metab Dis 45(3):493\u2013501. https:\/\/doi.org\/10.1002\/jimd.12469","journal-title":"J Inherited Metab Dis"},{"key":"11506_CR15","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.omtm.2022.04.016","volume":"25","author":"Q Liang","year":"2022","unstructured":"Liang Q et al (2022) Lentiviral gene therapy prevents anti-human acid alpha-glucosidase antibody formation in murine Pompe disease. Mol Ther Methods Clin Dev 25:520\u2013532","journal-title":"Mol Ther Methods Clin Dev"},{"key":"11506_CR16","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.omtm.2020.04.023","volume":"17","author":"M Stok","year":"2020","unstructured":"Stok M et al (2020) Lentiviral hematopoietic stem cell gene therapy corrects murine Pompe disease. Mol Ther Methods Clin Dev 17:1014\u20131025","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"5","key":"11506_CR17","doi-asserted-by":"publisher","first-page":"427","DOI":"10.2217\/iim.13.49","volume":"5","author":"WY Aung","year":"2013","unstructured":"Aung WY, Mar S, Benzinger TL (2013) Diffusion tensor MRI as a biomarker in axonal and myelin damage. Imaging Med 5(5):427\u2013440","journal-title":"Imaging Med"},{"issue":"12","key":"11506_CR18","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1007\/s10654-016-0224-9","volume":"31","author":"MN Kooijman","year":"2016","unstructured":"Kooijman MN et al (2016) The generation R study: design and cohort update 2017. Eur J Epidemiol 31(12):1243\u20131264","journal-title":"Eur J Epidemiol"},{"issue":"1","key":"11506_CR19","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1176\/appi.ajp.2017.16070813","volume":"175","author":"RL Muetzel","year":"2018","unstructured":"Muetzel RL et al (2018) Tracking brain development and dimensional psychiatric symptoms in children: a longitudinal population-based neuroimaging study. Am J Psychiatry 175(1):54\u201362","journal-title":"Am J Psychiatry"},{"issue":"2","key":"11506_CR20","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.neuroimage.2011.09.015","volume":"62","author":"M Jenkinson","year":"2012","unstructured":"Jenkinson M et al (2012) Fsl. Neuroimage 62(2):782\u201390","journal-title":"Neuroimage"},{"key":"11506_CR21","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.neuroimage.2015.07.067","volume":"122","author":"JL Andersson","year":"2015","unstructured":"Andersson JL, Sotiropoulos SN (2015) Non-parametric representation and prediction of single- and multi-shell diffusion-weighted MRI data using Gaussian processes. Neuroimage 122:166\u201376","journal-title":"Neuroimage"},{"key":"11506_CR22","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.neuroimage.2013.03.015","volume":"76","author":"M de Groot","year":"2013","unstructured":"de Groot M et al (2013) Improving alignment in tract-based spatial statistics: evaluation and optimization of image registration. Neuroimage 76:400\u201311","journal-title":"Neuroimage"},{"issue":"5","key":"11506_CR23","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1002\/mrm.10609","volume":"50","author":"TE Behrens","year":"2003","unstructured":"Behrens TE et al (2003) Characterization and propagation of uncertainty in diffusion-weighted MR imaging. Magn Reson Med 50(5):1077\u201388","journal-title":"Magn Reson Med"},{"key":"11506_CR24","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.neuroimage.2015.06.014","volume":"119","author":"RL Muetzel","year":"2015","unstructured":"Muetzel RL et al (2015) White matter integrity and cognitive performance in school-age children: a population-based neuroimaging study. Neuroimage 119:119\u201328","journal-title":"Neuroimage"},{"issue":"2","key":"11506_CR25","doi-asserted-by":"publisher","first-page":"351","DOI":"10.2214\/ajr.149.2.351","volume":"149","author":"F Fazekas","year":"1987","unstructured":"Fazekas F et al (1987) MR signal abnormalities at 1.5 T in Alzheimer\u2019s dementia and normal aging. AJR Am J Roentgenol 149(2):351\u20136","journal-title":"AJR Am J Roentgenol"},{"issue":"9","key":"11506_CR26","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1093\/cercor\/bhp280","volume":"20","author":"LT Westlye","year":"2010","unstructured":"Westlye LT et al (2010) Life-span changes of the human brain white matter: diffusion tensor imaging (DTI) and volumetry. Cereb Cortex 20(9):2055\u201368","journal-title":"Cereb Cortex"},{"issue":"1","key":"11506_CR27","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.neuroimage.2011.11.094","volume":"60","author":"C Lebel","year":"2012","unstructured":"Lebel C et al (2012) Diffusion tensor imaging of white matter tract evolution over the lifespan. Neuroimage 60(1):340\u201352","journal-title":"Neuroimage"},{"issue":"2","key":"11506_CR28","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/S1071-9091(99)80035-7","volume":"6","author":"C Beaulieu","year":"1999","unstructured":"Beaulieu C et al (1999) Diffusion-weighted magnetic resonance imaging: theory and potential applications to child neurology. Semin Pediatr Neurol 6(2):87\u2013100","journal-title":"Semin Pediatr Neurol"},{"issue":"1","key":"11506_CR29","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/jon.12374","volume":"27","author":"M Mascalchi","year":"2017","unstructured":"Mascalchi M et al (2017) Diffusion tensor imaging to map brain microstructural changes in CADASIL. J Neuroimaging 27(1):85\u201391","journal-title":"J Neuroimaging"},{"issue":"5","key":"11506_CR30","first-page":"819","volume":"24","author":"JF Schneider","year":"2003","unstructured":"Schneider JF et al (2003) Diffusion tensor imaging in cases of adrenoleukodystrophy: preliminary experience as a marker for early demyelination? AJNR Am J Neuroradiol 24(5):819\u201324","journal-title":"AJNR Am J Neuroradiol"},{"issue":"Pt 12","key":"11506_CR31","doi-asserted-by":"publisher","first-page":"3286","DOI":"10.1093\/brain\/awn265","volume":"131","author":"AA Gouw","year":"2008","unstructured":"Gouw AA et al (2008) Heterogeneity of white matter hyperintensities in Alzheimer\u2019s disease: post-mortem quantitative MRI and neuropathology. Brain 131(Pt 12):3286\u201398","journal-title":"Brain"},{"issue":"3","key":"11506_CR32","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s00415-018-8765-3","volume":"265","author":"DF van Rappard","year":"2018","unstructured":"van Rappard DF et al (2018) Diffusion tensor imaging in metachromatic leukodystrophy. J Neurol 265(3):659\u2013668","journal-title":"J Neurol"},{"key":"11506_CR33","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.nicl.2014.09.014","volume":"7","author":"A Gupta","year":"2015","unstructured":"Gupta A et al (2015) Regional differences in fiber tractography predict neurodevelopmental outcomes in neonates with infantile Krabbe disease. Neuroimage Clin 7:792\u20138","journal-title":"Neuroimage Clin"},{"issue":"5","key":"11506_CR34","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1007\/s10545-011-9361-1","volume":"34","author":"S Groeschel","year":"2011","unstructured":"Groeschel S et al (2011) Metachromatic leukodystrophy: natural course of cerebral MRI changes in relation to clinical course. J Inherit Metab Dis 34(5):1095\u2013102","journal-title":"J Inherit Metab Dis"},{"issue":"3","key":"11506_CR35","first-page":"442","volume":"26","author":"JP van der Voorn","year":"2005","unstructured":"van der Voorn JP et al (2005) Histopathologic correlates of radial stripes on MR images in lysosomal storage disorders. AJNR Am J Neuroradiol 26(3):442\u20136","journal-title":"AJNR Am J Neuroradiol"},{"issue":"2","key":"11506_CR36","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.pediatrneurol.2013.10.001","volume":"50","author":"AN Abdelhalim","year":"2014","unstructured":"Abdelhalim AN et al (2014) Patterns of magnetic resonance imaging abnormalities in symptomatic patients with Krabbe disease correspond to phenotype. Pediatr Neurol 50(2):127\u201334","journal-title":"Pediatr Neurol"},{"issue":"3","key":"11506_CR37","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1097\/00005072-197107000-00008","volume":"30","author":"P Gambetti","year":"1971","unstructured":"Gambetti P, DiMauro S, Baker L (1971) Nervous system in Pompe\u2019s disease. Ultrastructure and biochemistry. J Neuropathol Exp Neurol 30(3):412\u201330","journal-title":"J Neuropathol Exp Neurol"},{"issue":"3","key":"11506_CR38","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/BF00687878","volume":"23","author":"JJ Martin","year":"1973","unstructured":"Martin JJ et al (1973) Pompe\u2019s disease: an inborn lysosomal disorder with storage of glycogen: a study of brain and striated muscle. Acta Neuropathol (Berl) 23(3):229\u201344","journal-title":"Acta Neuropathol (Berl)"},{"key":"11506_CR39","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.msard.2019.02.021","volume":"30","author":"R Manca","year":"2019","unstructured":"Manca R et al (2019) Cognitive speed and white matter integrity in secondary progressive multiple sclerosis. Mult Scler Relat Disord 30:198\u2013207","journal-title":"Mult Scler Relat Disord"},{"issue":"6","key":"11506_CR40","doi-asserted-by":"publisher","first-page":"e718","DOI":"10.1212\/WNL.0000000000009979","volume":"95","author":"A Korlimarla","year":"2020","unstructured":"Korlimarla A et al (2020) Novel approaches to quantify CNS involvement in children with Pompe disease. Neurology 95(6):e718\u2013e732","journal-title":"Neurology"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-022-11506-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-022-11506-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-022-11506-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,27]],"date-time":"2023-02-27T13:09:03Z","timestamp":1677503343000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-022-11506-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,8]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["11506"],"URL":"https:\/\/doi.org\/10.1007\/s00415-022-11506-z","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,8]]},"assertion":[{"value":"28 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"J. van den Dorpel, M. Dremmen, D. Rizopoulos, R Muetzel and P. van Doorn report no competing interests. A. van der Ploeg received funding for research, clinical trials and as advisor from Sanofi-Genzyme, Amicus Therapeutics, Biomarin, Ultragenix, Sarepta, Audentes and Spark Therapeutics on enzyme replacement therapy or next-generation therapies in the field of Pompe disease, other lysosomal storage diseases or neuromuscular disorders, under agreements with Erasmus MC University Medical Center. N. van der Beek received funding for research, clinical trials and as advisor from Sanofi-Genzyme, Amicus Therapeutics, Biomarin and Spark Therapeutics on enzyme replacement therapy or next-generation therapies in the field of Pompe disease or neuromuscular disorders, under agreements with Erasmus MC University Medical Center. J. van den Hout received funding for research, clinical trials and as advisor from Sanofi Genzyme, Amicus Therapeutics, Biomarin, Sarepta, Takeda and Chiesi working on enzyme replacement therapy or next-generation therapies in the field of Pompe disease, other lysosomal storage diseases, under agreements with Erasmus MC University Medical Center.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000. This study was approved by the Institutional Review Board at the Erasmus MC University Medical Center (MEC-2007-103; amendment 11).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all patients for being included in the study. All forms are on file and available in case of request.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}